(Q44675344)

5 December 2017

title

Amisulpride is an "atypical" antipsychotic associated with low weight gain (English)

1 reference

5 December 2017

1 reference

4

Werner Kissling

1 reference

5 December 2017

1

Stefan Leucht

1 reference

5 December 2017

Stefan Wagenpfeil

2

1 reference

5 December 2017

Johannes Hamann

series ordinal

3

1 reference

5 December 2017

publication date

28 November 2003

1 reference

5 December 2017

1 reference

5 December 2017

volume

173

1 reference

5 December 2017

issue

1-2

1 reference

5 December 2017

page(s)

112-115

1 reference

https://scigraph.springernature.com/pub.10.1007/s00213-003-1721-6

5 December 2017

exact match

0 references

cites work

The long-term effect of quetiapine (Seroquel TM ) monotherapy on weight in patients with schizophrenia

1 reference

12 December 2020

Clinical, EEG mapping and psychometric studies in negative schizophrenia: comparative trials with amisulpride and fluphenazine.

1 reference

12 December 2020

Amisulpride versus haloperidol in treatment of schizophrenic patients--results of a double-blind study

1 reference

12 December 2020

Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia

1 reference

12 December 2020

Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group).

1 reference

12 December 2020

Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group

1 reference

12 December 2020

Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group.

1 reference

12 December 2020

Atypical antipsychotics and weight gain--a systematic review

1 reference

12 December 2020

Dropout rates in randomised antipsychotic drug trials

1 reference

12 December 2020

What is an atypical antipsychotic?

1 reference

12 December 2020

Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology -- a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group

1 reference

12 December 2020

Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia

1 reference

12 December 2020

Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials.

1 reference

12 December 2020

Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group

1 reference

12 December 2020

Antipsychotic-induced weight gain: a comprehensive research synthesis

1 reference

12 December 2020

Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity.

1 reference

12 December 2020

Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study

1 reference

12 December 2020

Treatment of negative symptoms in schizophrenia with amisulpride

1 reference

12 December 2020

One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride v. haloperidol

1 reference

12 December 2020

Improvement of some schizophrenic deficit symptoms with low doses of amisulpride

1 reference

12 December 2020

Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group

1 reference

12 December 2020

Amisulpride: from animal pharmacology to therapeutic action

1 reference

12 December 2020

Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients

1 reference

12 December 2020

10.1007/S00213-003-1721-6

Identifiers

DOI

1 reference

5 December 2017

1 reference